This is a preview of subscription content, log in via an institution to check access.
Reference
Mattingly II TJ, et al. Cost-Effectiveness of Grazoprevir / Elbasvir in Patients with Chronic Hepatitis C Virus. 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PIN47, 29 Oct 2016. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=47412.
Rights and permissions
About this article
Cite this article
Grazoprevir/elbasvir cost effective for HCV genotypes 1 and 4. PharmacoEcon Outcomes News 767, 14 (2016). https://doi.org/10.1007/s40274-016-3574-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3574-3